Rapid review and meta‐analysis of adverse events associated with molnupiravir in patients with COVID‐19
Author:
Affiliation:
1. Department of Health Management and Economics, School of Public Health Tehran University of Medical Sciences Tehran Iran
2. Department of Cell and Molecular Biology, Faculty of Biological Sciences Kharazmi University Tehran Iran
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15449
Reference35 articles.
1. Virology, Epidemiology, Pathogenesis, and Control of COVID-19
2. Medical treatment options for COVID-19
3. Controversial treatments: An updated understanding of the coronavirus disease 2019
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Molnupiravir Use Among Patients with COVID-19 in Real-World Settings: A Systematic Literature Review;Infectious Diseases and Therapy;2024-05-14
2. Safety of RNA-Dependent RNA Polymerase Inhibitors, Molnupiravir and VV116, for Oral Treatment of COVID-19: A Meta-Analysis;IRAN J MED SCI;2024
3. Comparison of effectiveness and safety of molnupiravir versus sotrovimab for COVID‐19: A systematic review and meta‐analysis;Immunity, Inflammation and Disease;2024-04
4. Small-molecule antiviral treatments for COVID-19: A systematic review and network meta-analysis;International Journal of Antimicrobial Agents;2024-03
5. Exploring Paxlovid Efficacy in COVID-19 Patients with MAFLD: Insights from a Single-Center Prospective Cohort Study;Viruses;2024-01-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3